


To provide a high and growing level of income with prospects for long-term capital growth.
| Name | % Net Assets |
|---|---|
| Astrazeneca | 2.0% |
| Unilever | 1.9% |
| GlaxoSmithKline | 1.9% |
| Vodafone Group | 1.9% |
| BT Group plc 7.50% 2016 | 1.7% |
| BP | 1.7% |
| Royal Dutch Shell B | 1.7% |
| BT Group | 1.6% |
| 4¼% Treasury Stock 2032 | 1.6% |
| Bear Stearns Co 5.375% MTN 18/10/2013 | 1.5% |
| Key | % Net Assets |
|---|---|
| 2.0% | |
| 1.9% | |
| 1.9% | |
| 1.9% | |
| 92.3% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 204.46p |
| Currency | GBP |
| Change | -0.13p |
| % | -0.06% |
| YTD change | 4.70p |
| YTD % | 2.35% |
| Fund Inception | 20/06/1974 |
|---|---|
| Fund Manager | Scott McKenzie / Robert Webb |
| TER | 0.83 (15-Apr-2012) |
| Minimum Investment | |
|---|---|
| Initial | £500000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.60% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.14 |
You are here: research